OncoSenX
OncoSenX develops targeted cancer therapies that use a proteo-lipid vehicle to deliver plasmid DNA, inducing apoptosis in cancer cells based on their transcriptional activity. Its approach aims to precisely target solid tumors while minimizing side effects and avoiding harm to healthy cells.
Facts
- HQ
- Seattle, Washington
- Sectors
- Biotechnology, Therapeutics, Oncology
- Stage
- Seed
- Members see funding amounts. .
Is this your organization? Claim it
Recent coverage
Front-page news, podcasts and videos about OncoSenX
OncoSenX extends oversubscribed SAFE, plans $30M Series A to fund Phase I for genetics-targeted cancer therapies
Seattle biotech OncoSenX extended an oversubscribed SAFE to raise more capital for its lipid nanoparticle gene-delivery cancer therapies and plans a $30 million Series A to fund a Phase I trial; the spinout has raised $4.1 million so far and has six employees.
OncoSenX raises $3M to advance non-viral, gene-delivery cancer therapeutics targeting solid tumors
Seattle startup OncoSenX raised $3 million to advance a non-viral, lipid nanoparticle gene-delivery platform that aims to selectively kill solid tumor cells based on their genetic mutations, and plans to use the funding to accelerate preclinical work toward Phase 1 trials.
People
-
Eric Garcia Executive, Chief Operating Officer
-
Matthew Scholz Executive, Chief Executive Officer
-
Stephen Hilbert Executive, Chief Business Officer
Online
Questions about OncoSenX
What is OncoSenX?
OncoSenX is a startup based in Seattle, Washington that develops targeted cancer therapies using a proteo-lipid vehicle to deliver plasmid DNA and induce cancer-cell death based on transcriptional activity.
What has OncoSenX been in the news for?
GeekWire reported in May 2020 on OncoSenX's plans for Phase I development of genetics-targeted cancer therapies. In July 2019, GeekWire reported on OncoSenX's work to advance non-viral, gene-delivery cancer therapeutics targeting solid tumors.
Who are the people behind OncoSenX?
Matthew Scholz is chief executive officer of OncoSenX, Eric Garcia is chief operating officer, and Stephen Hilbert is chief business officer.
Who invested in OncoSenX, and how much has it raised?
Members of Seattle Flow see OncoSenX's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is OncoSenX based?
OncoSenX is based in Seattle, Washington.